Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China flag China · Delayed Price · Currency is CNY
16.15
-0.34 (-2.06%)
Nov 17, 2026, 3:04 PM CST

SHE:300204 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
555.82123.6453.9185.18264.9985.01
Trading Asset Securities
500.23----381.46
Cash & Short-Term Investments
1,056123.6453.9185.18264.99466.47
Cash Growth
568.39%129.34%-36.71%-67.86%-43.19%-35.44%
Accounts Receivable
45.3241.5239.0761.22188.18157.9
Other Receivables
1.111.220.641.141.381.18
Receivables
46.4442.7539.7262.35189.56159.07
Inventory
18.5419.322.1820.9318.8325.01
Prepaid Expenses
-00.010.01--
Other Current Assets
173.5666.9761.870.4155.6937.9
Total Current Assets
1,295252.65177.62238.89529.06688.44
Property, Plant & Equipment
194.55211.79235261.36290.58312.43
Long-Term Investments
485.52475.02514.07549.54522.25545.43
Goodwill
19.7519.7519.7519.7519.7522.17
Other Intangible Assets
157.5636.3634.6735.1380.4882.22
Long-Term Deferred Tax Assets
50.4250.4250.08164198.13155.84
Long-Term Deferred Charges
112.86186.77117.8462.5726.975.29
Other Long-Term Assets
46.7733.450.580.982.0915.15
Total Assets
2,3621,2661,1501,3321,6691,827

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
11.9121.9233.4972.9135.8731.71
Accrued Expenses
9.0752.6967.7183.85158.73150.01
Short-Term Debt
-92.2742.4240.9523.09-
Current Portion of Leases
0.380.430.06-2.692.25
Current Income Taxes Payable
4.640--0.02-
Current Unearned Revenue
1.551.263.892.863.271.34
Other Current Liabilities
45.476.996.887.68.111.33
Total Current Liabilities
73.02175.55154.45208.17231.77196.64
Long-Term Leases
0.390.670.06-3.185.37
Long-Term Unearned Revenue
29.5626.7629.9129.2433.4721.32
Long-Term Deferred Tax Liabilities
49.2449.2448.4374.1447.0352.91
Other Long-Term Liabilities
216.24207.27----
Total Liabilities
368.45459.48232.85311.55315.45276.25

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
541.34477.77477.77477.77475.36476.03
Additional Paid-In Capital
1,723558.6570.95534.46519.36536.44
Retained Earnings
-382.07-327.12-249.37-83.63314.62510.98
Treasury Stock
------43.68
Comprehensive Income & Other
128.38111.53129.8892.0644.5370.97
Total Common Equity
2,011820.78929.231,0211,3541,551
Minority Interest
-17.11-14.06-12.47---
Shareholders' Equity
1,994806.72916.761,0211,3541,551
Total Liabilities & Equity
2,3621,2661,1501,3321,6691,827

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
0.7693.3642.5440.9528.967.63
Net Cash (Debt)
1,05530.2811.3744.23236.03458.84
Net Cash Growth
807.65%166.24%-74.28%-81.26%-48.56%-31.98%
Net Cash Per Share
2.290.060.020.090.490.97
Filing Date Shares Outstanding
541.34477.77477.77477.77475.36472.66
Total Common Shares Outstanding
541.34477.77477.77477.77475.36472.66
Working Capital
1,22277.123.1830.72297.28491.8
Book Value Per Share
3.711.721.942.142.853.28
Tangible Book Value
1,833764.67874.81965.781,2541,446
Tangible Book Value Per Share
3.391.601.832.022.643.06
Buildings
-215.73215.93214.75184.57183.64
Machinery
-302.85317.62318.38254.98246.28
Construction In Progress
----87.8285.48